373 related articles for article (PubMed ID: 17597710)
21. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
23. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF; Zhou ZW; Huang M
Toxicology; 2010 Dec; 278(2):165-88. PubMed ID: 19715737
[TBL] [Abstract][Full Text] [Related]
25. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.
Vormfelde SV; Brockmöller J; Bauer S; Herchenhein P; Kuon J; Meineke I; Roots I; Kirchheiner J
Clin Pharmacol Ther; 2009 Jul; 86(1):54-61. PubMed ID: 19369937
[TBL] [Abstract][Full Text] [Related]
26. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
[TBL] [Abstract][Full Text] [Related]
27. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
28. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
29. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
[TBL] [Abstract][Full Text] [Related]
30. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH
Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303
[TBL] [Abstract][Full Text] [Related]
31. Genetic Polymorphisms of Cytochrome p450 (2C9) Enzyme in Patients with Type 2 Diabetes Mellitus in Turkmen and Fars Ethnic Groups.
Rabiee M; Marjani A; Khajeniazi S; Mojerloo M
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):653-661. PubMed ID: 30129421
[TBL] [Abstract][Full Text] [Related]
32. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
33. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
34. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
35. Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
Ikeda T; Aoyama S; Tozuka Z; Nozawa K; Hamabe Y; Matsui T; Kainuma M; Hasegawa S; Maeda K; Sugiyama Y
Eur J Pharm Sci; 2013 Jul; 49(4):642-8. PubMed ID: 23727057
[TBL] [Abstract][Full Text] [Related]
36. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
Tirkkonen T; Heikkilä P; Huupponen R; Laine K
J Intern Med; 2010 Oct; 268(4):359-66. PubMed ID: 20698928
[TBL] [Abstract][Full Text] [Related]
37. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.
Fasano CJ; O'Malley G; Dominici P; Aguilera E; Latta DR
Ann Emerg Med; 2008 Apr; 51(4):400-6. PubMed ID: 17764782
[TBL] [Abstract][Full Text] [Related]
38. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
[TBL] [Abstract][Full Text] [Related]
39. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.
Surendiran A; Pradhan SC; Agrawal A; Subrahmanyam DK; Rajan S; Anichavezhi D; Adithan C
Eur J Clin Pharmacol; 2011 Aug; 67(8):797-801. PubMed ID: 21336994
[TBL] [Abstract][Full Text] [Related]
40. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
Yildirim H; Tamer L; Sucu N; Atik U
Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
